A new drug to treat moderate-to-severe plaque psoriasis carries a black box warning that suicidal ideas and behavior, including completed suicides, have occurred in patients during the drug’s clinical trials.
A pioneering summit between healthcare payers and groups pursuing standardized outcome measures in dermatology has revealed that payers want outcome measures that are published, universally accepted and practical both for clinicians and payers.
The FDA is evaluating biosimilar medications for use in the United States. The approval of these medications in the next few years could mean big changes for dermatologists and their psoriasis patients
As research advances understanding of psoriasis, drug development evolves to address various pathways to disease. A number of possibilities, now in clinical trials, appear safe, effective and promising with improved long-term clearance rates.